160 345

Cited 0 times in

Delay in Vaccine Access in Asia-Pacific countries

Other Titles
 아시아 국가들의 백신 접근성 지연에 관한 연구 
Authors
 Subsittipong, Nilubon 
College
 College of Medicine (의과대학) 
Department
 Others (기타) 
Degree
석사
Issue Date
2021-08
Abstract
Background: The introduction of new vaccines has been delayed in some Asia-Pacific countries and lead to delay in vaccine access for target patients. However, the approval lag of vaccine in Asia-Pacific countriess has not been assessed. This study aimed to evaluate the availability and approval lag of vaccines in Asia-Pacific countries and compare with the United States (US), and European Union (EU). Methods: The information of vaccines prequalified by the World Health Organization (WHO) between 2010 and 2019 was obtained primarily from WHO website. The date of approval of WHO prequalified vaccines in Australia, India, South Korea, Thailand, Singapore, Malaysia, US and EU were retrieved from the official website of national regulatory agencies. The vaccines were divided into 2 groups based on their first approval pathway, i.e., vaccines that first approved by SRA and those that first by non-SRA. Absolute approval lag was the availability of vaccines. Relative approval lag was calculated from the lag time between the approval date in certain country and the first global approval date as median approval lag. Man-Whitney U Test was used to assess statistical differences between relative approval lag between SRA first and non-SRA first group. Results: Total of 92 vaccines were prequalified by WHO between 2010 and 2019, but only 61 vaccines were included in the analysis. Over 50% of vaccines were first licensed by Non-SRAs. Of all WHO-prequalified vaccine, the median approval lag in Asia Pacific countries was longer than those in the US and EU, with 30 months in Australia, 15 months in South Korea, 52 months in Thailand, and 23 months in Singapore compared to 0 months in the US and EU. The differences in approval lag between SRA first vaccines and Non-SRA first vaccines were statistically significant in South Korea and India (P <0.05). Conclusions: The approval lag of vaccines was observed in the Asia-pacific countries, indicating a gap between Asia-Pacific countries, the US, and EU in regard to access to new vaccines. Future studies need to analyze the background factors related to the gap in the availability and vaccine approval lag in Asia-Pacific countries and assess the impact of vaccine approval lag.
Files in This Item:
TA03010.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Others (기타) > 2. Thesis
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/185534
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links